Patient, CLL, and transplantation characteristics
| Characteristic . | CLL-RT patients . | CLL patients with no RT . | All CLL patients . |
|---|---|---|---|
| No. of patients | 23 | 35 | 58 |
| Sex | |||
| Female | 5 | 8 | 13 |
| Male | 18 | 27 | 45 |
| Median age, y (range) | 57.6 (36.3-69.6) | 54.5 (43.4-67.9) | 55 (36.3-69.6) |
| Median time from diagnosis to HSCT, mo | 73.9 (7.9-241.2) | 65.8 (13.1-206.0) | 73.1 (7.9-241.2) |
| Rai stage | |||
| 0 | 5 | 3 | 8 |
| 1 | 10 | 15 | 25 |
| 2 | 5 | 9 | 14 |
| 3 | 1 | 5 | 6 |
| 4 | 2 | 3 | 5 |
| Patients with adverse cytogenetics or molecular features | 14 (60.9) | 30 (85.7) | 44 (75.9) |
| TP53 mutation/del17p | 4 | 12 | 16 |
| IGHV unmutated | 8 | 5 | 13 |
| ZAP70+ | 0 | 8 | 8 |
| del11q | 4 | 16 | 20 |
| Complex | 2 | 7 | 9 |
| HSCT Comorbidity Index score | |||
| 0 | 9 | 11 | 20 |
| 1-2 | 3 | 16 | 19 |
| 3-4 | 7 | 6 | 13 |
| ≥5 | 4 | 2 | 6 |
| Disease response status at time of HSCT | |||
| CR | 7 | 2 | 9 |
| PR | 12 | 23 | 35 |
| SD | 0 | 9 | 9 |
| PD | 4 | 1 | 5 |
| Median No. of previous lines of therapy (range) | Total: 3 (1-9); 2 (1-4) for RT | 3 (1-10) | 3 (1-10) |
| Previous use of novel agent | 2 (8.7) | 9 (25.7) | 11 (19.0) |
| Novel agent | |||
| Ibrutinib | 2 | 8 | 9 |
| Venetoclax | 1 | 4 | 5 |
| Idelalisib/duvelisib | 0 | 3 | 3 |
| Conditioning regimen | |||
| Rituximab-fludarabine-cyclophosphamide-TBI 200 | 14 | 18 | 32 |
| Fludarabine-cyclophosphamide-TBI 200 | 1 | 3 | 4 |
| Fludarabine-cyclophosphamide-thiotepa-TBI 400 | 2 | 2 | 4 |
| Fludarabine-melphalan | 4 | 4 | 8 |
| Fludarabine-melphalan-thiotepa | 2 | 2 | 4 |
| Rituximab-fludarabine-busulfan | 0 | 3 | 3 |
| Fludarabine-busulfan | 0 | 3 | 3 |
| Use of ATG | |||
| Yes | 10 | 13 | 23 |
| No | 13 | 22 | 35 |
| Graft source | |||
| MRD PBSC | 6 | 13 | 19 |
| MUD PBSC | 6 | 13 | 19 |
| Haplo PBSC | 2 | 0 | 2 |
| Haplo bone marrow | 0 | 2 | 2 |
| MMUD PBSC | 4 | 3 | 7 |
| Cord blood transplant | 5 | 4 | 9 |
| Characteristic . | CLL-RT patients . | CLL patients with no RT . | All CLL patients . |
|---|---|---|---|
| No. of patients | 23 | 35 | 58 |
| Sex | |||
| Female | 5 | 8 | 13 |
| Male | 18 | 27 | 45 |
| Median age, y (range) | 57.6 (36.3-69.6) | 54.5 (43.4-67.9) | 55 (36.3-69.6) |
| Median time from diagnosis to HSCT, mo | 73.9 (7.9-241.2) | 65.8 (13.1-206.0) | 73.1 (7.9-241.2) |
| Rai stage | |||
| 0 | 5 | 3 | 8 |
| 1 | 10 | 15 | 25 |
| 2 | 5 | 9 | 14 |
| 3 | 1 | 5 | 6 |
| 4 | 2 | 3 | 5 |
| Patients with adverse cytogenetics or molecular features | 14 (60.9) | 30 (85.7) | 44 (75.9) |
| TP53 mutation/del17p | 4 | 12 | 16 |
| IGHV unmutated | 8 | 5 | 13 |
| ZAP70+ | 0 | 8 | 8 |
| del11q | 4 | 16 | 20 |
| Complex | 2 | 7 | 9 |
| HSCT Comorbidity Index score | |||
| 0 | 9 | 11 | 20 |
| 1-2 | 3 | 16 | 19 |
| 3-4 | 7 | 6 | 13 |
| ≥5 | 4 | 2 | 6 |
| Disease response status at time of HSCT | |||
| CR | 7 | 2 | 9 |
| PR | 12 | 23 | 35 |
| SD | 0 | 9 | 9 |
| PD | 4 | 1 | 5 |
| Median No. of previous lines of therapy (range) | Total: 3 (1-9); 2 (1-4) for RT | 3 (1-10) | 3 (1-10) |
| Previous use of novel agent | 2 (8.7) | 9 (25.7) | 11 (19.0) |
| Novel agent | |||
| Ibrutinib | 2 | 8 | 9 |
| Venetoclax | 1 | 4 | 5 |
| Idelalisib/duvelisib | 0 | 3 | 3 |
| Conditioning regimen | |||
| Rituximab-fludarabine-cyclophosphamide-TBI 200 | 14 | 18 | 32 |
| Fludarabine-cyclophosphamide-TBI 200 | 1 | 3 | 4 |
| Fludarabine-cyclophosphamide-thiotepa-TBI 400 | 2 | 2 | 4 |
| Fludarabine-melphalan | 4 | 4 | 8 |
| Fludarabine-melphalan-thiotepa | 2 | 2 | 4 |
| Rituximab-fludarabine-busulfan | 0 | 3 | 3 |
| Fludarabine-busulfan | 0 | 3 | 3 |
| Use of ATG | |||
| Yes | 10 | 13 | 23 |
| No | 13 | 22 | 35 |
| Graft source | |||
| MRD PBSC | 6 | 13 | 19 |
| MUD PBSC | 6 | 13 | 19 |
| Haplo PBSC | 2 | 0 | 2 |
| Haplo bone marrow | 0 | 2 | 2 |
| MMUD PBSC | 4 | 3 | 7 |
| Cord blood transplant | 5 | 4 | 9 |
Haplo, HLA-haploidentical; MMUD, HLA-mismatched unrelated donor; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; PBSC, peripheral blood stem cell; TBI 200, total body irradiation 200 cGy; TBI 400, total body irradiation 400 cGy.